Literature DB >> 1677556

Applications of restriction fragment length polymorphism.

S Narayanan1.   

Abstract

The availability of a variety of restriction endonuclease enzymes that cleave deoxyribonucleic acid (DNA) at specific sites has made it possible to identify the presence of polymorphic regions in the isolated fragments. Such restriction fragment length polymorphism (RFLP) results owing to a variation in the number of tandem repeats (VNTR) of a short DNA segment. These VNTR sequences can uniquely specify an individual and, as such, are used in DNA fingerprinting and in paternity testing. Restriction fragment length polymorphism may be found close to a disease gene, and, as such, can be used as a genetic disease marker. Certain criteria need to be fulfilled, however, for RFLP to be useful as a genetic disease marker, such as its closeness to the disease gene. Materials and methodology for detecting RFLP are reviewed with the current emphasis on amplification procedures utilizing the polymerase chain reaction (PCR).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677556

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  4 in total

Review 1.  Analysis of single nucleic acid molecules in micro- and nano-fluidics.

Authors:  Sarah M Friedrich; Helena C Zec; Tza-Huei Wang
Journal:  Lab Chip       Date:  2016-03-07       Impact factor: 6.799

Review 2.  A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.

Authors:  Liang Ma; Ousmane H Cissé; Joseph A Kovacs
Journal:  Clin Microbiol Rev       Date:  2018-06-13       Impact factor: 26.132

3.  Allele-Specific Quantitative PCR for Accurate, Rapid, and Cost-Effective Genotyping.

Authors:  Han B Lee; Tanya L Schwab; Alaa Koleilat; Hirotaka Ata; Camden L Daby; Roberto Lopez Cervera; Melissa S McNulty; Hannah S Bostwick; Karl J Clark
Journal:  Hum Gene Ther       Date:  2016-03-17       Impact factor: 5.695

4.  Comparison of multiple genotyping methods for the identification of the cancer predisposing founder mutation p.R337H in TP53.

Authors:  Mariana Fitarelli-Kiehl; Gabriel S Macedo; Rosane Paixão Schlatter; Patricia Koehler-Santos; Ursula da Silveira Matte; Patricia Ashton-Prolla; Juliana Giacomazzi
Journal:  Genet Mol Biol       Date:  2016-06-03       Impact factor: 1.771

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.